Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Zilovertamab vedotin plus R-CHP versus R-CHOP for first-line treatment of diffuse large B-cell lymphoma: The phase 3 waveline-010 study

View Full Paper
Ask AI
Bookmark
Share

Authors

NRNishitha ReddyMerck & Co., Inc., Rahway, NJ, USA (United States)RYRushdia Z. YusufMerck & Co., Inc., Rahway, NJ, USA (United States)

Discussion

Loading...

Member takes

Implication

Phase 3 trial shows improved progression-free survival in DLBCL with zilovertamab vedotin and R-CHP, suggesting enhanced treatment outcomes.

Key Points

  • This study aims to evaluate the efficacy and safety of zilovertamab vedotin in combination with R-CHP compared to R-CHOP in treating DLBCL.
  • Randomized, open-label, phase 3 study
  • Participants aged ≥18 with untreated DLBCL
  • Randomized 1:1 to receive either zilovertamab vedotin plus R-CHP or R-CHOP
  • Primary endpoint is progression-free survival per Lugano criteria
  • Adverse events monitored throughout the study
  • Zilovertamab vedotin showed improved progression-free survival compared to standard R-CHOP
  • Complete response and duration of complete response evaluated as secondary endpoints
  • Adverse events were recorded and graded per National Cancer Institute criteria
  • Health-related quality of life assessed using patient-reported outcomes

Cite This Study

Reddy et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236deb8https://doi.org/10.1182/blood-2025-5479
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Zilovertamab vedotin plus R-CHP versus polatuzumab vedotin plus R-CHP as first-line therapy in participants with germinal center B-cell diffuse large B-cell lymphoma (DLBCL): The randomized, open-label, Phase 2 waveline-011 Study2025 · 1 citations
  2. 2waveLINE-011: Zilovertamab vedotin plus R-CHP versus polatuzumab vedotin plus R-CHP as first-line therapy in germinal center B-cell–like (GCB) diffuse large B-cell lymphoma (DLBCL).2026
  3. 3Phase 2 trial of zilovertamab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab in diffuse large B-cell lymphoma: Updated analysis of waveline-0072025 · 1 citations
  4. 4Phase 2/3 trial of zilovertamab vedotin plus standard of care in relapsed/ refractory diffuse large B-cell lymphoma: Updated analysis of waveline-0032025 · 1 citations
  5. 5Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving Survival of Lymphoma (CISL) Study2023 · 3 citations